Biotechnology
Price
$131.27
+4.21%Market Cap
$162.98B
Day High
$131.58
Day Low
$126.46
Gilead Sciences delivered a strong Q1 FY2026 with revenue up 4.4% to $6.96B, net income surging 53.7% to $2.02B, and operating cash flow jumping 44.8% to $2.54B, driven by lower cost of revenue and improved operating leverage.
Key risk: High Long-Term Debt Burden
Despite a reduction, Gilead carries $22.17B in long-term debt, which represents a significant financial obligation. Rising interest rates or revenue shortfalls could strain debt servicing capacity and limit strategic flexibility.
Other Biotechnology companies